Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis in Clinical Trial Collaboration with Bristol Myers

06/14/2021 | 09:02am EDT

By Michael Dabaie

Exelixis Inc. said it is in a clinical trial collaboration and supply agreement with Bristol Myers Squibb Co. for a Phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors.

The objective of the study is to evaluate the safety, tolerability and efficacy of Exelixis' XL092, in combination with: nivolumab, or Opdivo; nivolumab and ipilimumab, or Yervoy; and nivolumab and bempegaldesleukin.

Exelixis said it is sponsoring the trial and Bristol Myers Squibb will provide nivolumab, ipilimumab and bempegaldesleukin for use in the trial.

Nektar Therapeutics will supply bempegaldesleukin to Bristol Myers Squibb through their existing global development and commercialization collaboration.

The STELLAR-002 study will begin with a dose-escalation phase to determine the recommend dose for each of the combination therapies.

Expansion cohorts to include patients with advanced kidney, prostate and bladder cancers, Exelixis said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

06-14-21 0901ET

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 1.90% 69.31 Delayed Quote.9.66%
EXELIXIS, INC. -1.51% 16.97 Delayed Quote.-15.45%
NEKTAR THERAPEUTICS -1.00% 15.8 Delayed Quote.-7.06%
All news about BRISTOL-MYERS SQUIBB COMPANY
08/03INSIDER TRENDS : Bristol-Myers Squibb Insider Converts Option/Derivative Securit..
MT
08/03INSIDER TRENDS : Bristol-Myers Squibb Insider Disposition Scales Back 90-Days of..
MT
08/03INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of Bristol..
MT
08/03BRISTOL MYERS SQUIBB : Completes Sale of Manufacturing Facility in Couvet, Switz..
BU
08/03BRISTOL MYERS SQUIBB : Statement on Istodax« (romidepsin) Relapsed/Refractory Pe..
PU
07/30BRISTOL MYERS SQUIBB : Receives European Commission Approval for Cancer Treatmen..
MT
07/30BRISTOL MYERS SQUIBB : Receives European Commission Approval for Opdivo (nivolum..
BU
07/30Bristol Myers Squibb Receives European Commission Approval for Opdivo as Adju..
CI
07/30Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or ..
DJ
07/29BRISTOL MYERS SQUIBB : Goldman Sachs Adjusts Price Target for Bristol-Myers Squi..
MT
More news
Financials (USD)
Sales 2021 46 338 M - -
Net income 2021 6 718 M - -
Net Debt 2021 25 775 M - -
P/E ratio 2021 22,7x
Yield 2021 2,81%
Capitalization 154 B 154 B -
EV / Sales 2021 3,88x
EV / Sales 2022 3,53x
Nbr of Employees 30 250
Free-Float 76,0%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 69,31 $
Average target price 76,33 $
Spread / Average Target 10,1%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY9.66%154 015
JOHNSON & JOHNSON10.81%453 498
ROCHE HOLDING AG13.88%339 298
PFIZER, INC.24.10%246 075
NOVARTIS AG0.14%225 528
ELI LILLY AND COMPANY51.62%224 166